Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Nat Med. 2012 Sep;18(9):1378–1385. doi: 10.1038/nm.2892

Figure 6.

Figure 6

Outcomes of DRV/r + RAL dual suppression therapy simulations, considering resistant mutants for both drugs. (a) Each drug is taken independently and adherence may differ between them. The brightness of each color at a particular point indicates the probability of the corresponding outcome, with the black contours showing where each outcome occurs 95% of the time. Success depends largely on adherence to DRV/r (almost certain if > 50%), while the type of failure is determined by adherence to RAL (resistance almost certain if > 30%). All failure via resistance is due to RAL mutant-based VF. DRV mutant-based virologic failure (VF) never occurs in the simulations. (b)–(c) Drugs are taken with equal average adherence. The height of the area shaded indicates probability of the corresponding outcome at that adherence level. (b) Drugs are taken as separate pills. Average adherence is the same but pills are taken independently. (c) Drugs are packaged as a combination pill and are always taken together. Mutant VF occurs only when the two drugs are given in separate pills; combination pills eliminate mutant VF but increase the adherence required for near-certain success.